Loading...

Viking Therapeutics, Inc.

0VQA.L•LSE
Healthcare
Medical - Pharmaceuticals
£30.60
£3.010(10.91%)

Viking Therapeutics, Inc. (0VQA.L) Stock Overview

Explore Viking Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.5/100

Key Financials

Market Cap3.7B
P/E Ratio-27.55
EPS (TTM)$-0.73
ROE-0.14%
Fundamental Analysis

AI Price Forecasts

1 Week$26.76
1 Month$24.69
3 Months$8.47
1 Year Target$66.70

0VQA.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Viking Therapeutics, Inc. (0VQA.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 64.92, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $66.70.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -27.55 and a market capitalization of 3.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

64.92RSI (14)
0.80MACD
17.54ADX
Revenue Growth
0.00%
Profit Growth
£-1.14
↓ 28.02%
EPS Growth
£-1.14
↓ 10.99%
Operating Margin
0.00%
↓ 49.68%
ROE
-14.41%
↓ 28.02%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 0VQA.LAnalyst Recommendations details for 0VQA.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

CEO

Brian Lian

Employees

45

Headquarters

9920 Pacific Heights Boulevard, San Diego, CA

Founded

2018

Frequently Asked Questions

;